- Home
- IRD vs ME Comparison
IRD vs ME Comparison
Compare IRD & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- ME
- Stock Information
- Founded
- IRD 2018
- ME 2006
- Country
- IRD United States
- ME United States
- Employees
- IRD N/A
- ME N/A
- Industry
- IRD
- ME Precision Instruments
- Sector
- IRD
- ME Health Care
- Exchange
- IRD NYSE
- ME Nasdaq
- Market Cap
- IRD 35.7M
- ME 40.0M
- IPO Year
- IRD N/A
- ME N/A
- Fundamental
- Price
- IRD $0.93
- ME $1.82
- Analyst Decision
- IRD Strong Buy
- ME Hold
- Analyst Count
- IRD 1
- ME 1
- Target Price
- IRD $8.00
- ME $9.40
- AVG Volume (30 Days)
- IRD 141.6K
- ME 466.4K
- Earning Date
- IRD 03-25-2025
- ME 01-28-2025
- Dividend Yield
- IRD N/A
- ME N/A
- EPS Growth
- IRD N/A
- ME N/A
- EPS
- IRD N/A
- ME N/A
- Revenue
- IRD $8,381,000.00
- ME $208,775,000.00
- Revenue This Year
- IRD N/A
- ME $22.00
- Revenue Next Year
- IRD $29.37
- ME $17.31
- P/E Ratio
- IRD N/A
- ME N/A
- Revenue Growth
- IRD N/A
- ME N/A
- 52 Week Low
- IRD $0.81
- ME $1.34
- 52 Week High
- IRD $2.34
- ME $12.76
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- ME 37.81
- Support Level
- IRD N/A
- ME $1.48
- Resistance Level
- IRD N/A
- ME $1.75
- Average True Range (ATR)
- IRD 0.00
- ME 0.17
- MACD
- IRD 0.00
- ME 0.02
- Stochastic Oscillator
- IRD 0.00
- ME 40.43
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.